ReportCancer

Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma

See allHide authors and affiliations

Science Translational Medicine  31 Jan 2018:
Vol. 10, Issue 426, eaan8723
DOI: 10.1126/scitranslmed.aan8723

Article Information

vol. 10 no. 426

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication May 31, 2017
  • Resubmitted November 8, 2017
  • Accepted for publication December 28, 2017

Author Information

  1. Micol Ravà1,2,*,
  2. Aleco D’Andrea1,*,,
  3. Paola Nicoli1,
  4. Ilaria Gritti1,,
  5. Giulio Donati1,
  6. Mirko Doni1,
  7. Marco Giorgio1,
  8. Daniela Olivero3 and
  9. Bruno Amati1,2,§
  1. 1Department of Experimental Oncology, European Institute of Oncology, Via Adamello 16, 20139 Milan, Italy.
  2. 2Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Via Adamello 16, 20139 Milan, Italy.
  3. 3Laboratorio Analisi Veterinarie BiEsseA, Via A. d’Aosta 7, 20129 Milan, Italy.
  1. §Corresponding author. Email: bruno.amati{at}ieo.it
    • * These authors contributed equally to this work.

    • Present address: QuintilesIMS, Via Roma 108, 20060 Cassina de’ Pecchi, Milan, Italy.

    • Present address: Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto San Raffaele, 20132 Milan, Italy.

    Altmetric

    Article usage

    Article usage: January 2018 to June 2019

    AbstractFullPdf
    Jan 20189972962
    Feb 20184470208398
    Mar 201841339110
    Apr 20182523265
    May 20182422056
    Jun 20182303555
    Jul 20181803053
    Aug 20181306245
    Sep 20181204719
    Oct 20181044935
    Nov 20181265551
    Dec 20181183828
    Jan 2019744031
    Feb 20191815149
    Mar 20191716378
    Apr 20191213475
    May 20191411855
    Jun 20191011460

    Navigate This Article